AI-powered embryonic phenotyping for accelerated drug discovery and toxicology

Projektbeschreibung

Fortgeschrittenes Deep Learning beschleunigt Wirkstoff- und Toxikologieforschung

Herkömmliche Arzneimittelprüfungen basieren auf Tiermodellen, die zeitaufwändig, kostspielig und ethisch problematisch sind. Das Ziel des ERC-finanzierten Projekts EmbryoNet-AI besteht darin, die Arzneimittelentdeckung und toxikologische Prüfungen zu verbessern, indem die phänotypische Analyse von Embryonen und Organoiden mithilfe von fortgeschrittenem Deep Learning automatisiert wird. Diese Plattform wird schnellere und genauere Bewertungen der Wirkungen von Verbindungen zulassen und somit die Abhängigkeit von Tiermodellen verringern. Mit dem Schwerpunkt auf Entwicklung und Kommerzialisierung wird das Projektteam KI-Modelle verfeinern, eine nutzungsfreundliche Webschnittstelle schaffen und mit Partnern zusammenarbeiten. Durch optimierte traditionelle Prüfverfahren werden im Rahmen von EmbryoNet-AI die Arzneimittelentdeckung beschleunigt, die Kosten gesenkt und die nachhaltige Forschung in der Entwicklungsbiologie und Pharmakologie unterstützt.

Ziel

The EmbryoNet-AI project seeks to transform drug discovery and toxicology testing by integrating advanced deep learning technologies to automate phenotypic analysis of embryos and organoids. Traditional drug testing methods rely heavily on animal models, which are time-consuming, costly, and often ethically problematic. EmbryoNet-AI offers a faster, more accurate, and comprehensive solution for evaluating the effects of compounds on biological development, thus significantly enhancing the efficiency of early-stage drug screening. The core innovation is EmbryoNet-AI's ability to analyze complex biological data with precision, providing insights into drug mechanisms that are not only quicker but also more reliable than current methods. This will ultimately reduce the need for animal models in drug testing, addressing both ethical and logistical concerns. The EmbryoNet-AI platform is poised to fill a critical gap in the pharmaceutical and biotech industries, offering a scalable, non-invasive approach that can be easily integrated into existing workflows. With the support of the ERC Proof of Concept grant, we will focus on the further development, validation, and commercialization of the EmbryoNet-AI platform. The project will involve refining our AI models through rigorous testing, building a prototype web interface for user interaction, and collaborating with industrial and academic partners to ensure the platforms practical utility. Additionally, we will explore intellectual property strategies and assess market readiness, paving the way for wide-spread adoption. By addressing the limitations of traditional phenotyping methods, EmbryoNet-AI aims to accelerate drug discovery, reduce costs, and promote more sustainable research practices in developmental biology and pharmacology. Through ERC funding, we aim to establish EmbryoNet-AI as a ground-breaking tool that will impact both the scientific community and the pharmaceutical industry.